Health Minister Datuk Seri Dr. Adham Baba said that the AstraZeneca vaccine will remain for the National Covid-19 Immunisation Programme (PICK)
Adham said that Malaysia will continue to use this vaccine because the available clinical data pointing to its benefit to the recipient as opposed to its harms.
This follows a report by medical regulators in Britain confirming that seven out of 30 individuals who suffered blood clots after being injected with AstraZeneca died and some European countries also decided to temporarily stop immunizing the vaccine despite the World Health Organization (WHO) confirming it is still safe.
Commenting further, Adham said, the Jawatankuasa Khas Jaminan Akses Vaksin (JKJAV) meeting which he chaired with Khairy also took note of various elements and factors from cases abroad.
The government has already ordered 6.4 million doses of the vaccine, which is produced from its plant in Thailand, in addition to another 1.4 million doses through the WHO-launched COVID-19 Vaccines Global Access (Covax).
Malaysia received a stock of 66.7 million doses from five manufacturers including Pfizer-BioNTech from the United States, Sinovac and Cansino from China and Sputnik V from Russia.